Brief: Redhill Biopharma Advances Opaganib Options For Ebola Virus Disease Outbreak
03/06/2026 17:46
BRIEF-Redhill Biopharma Advances Opaganib Options For Ebola Virus Disease Outbreak June 3 (Reuters) - Redhill Biopharma Ltd 2RHy.F:
REDHILL BIOPHARMA ADVANCING OPAGANIB OPTIONS FOR EBOLA VIRUS DISEASE OUTBREAK
REDHILL BIOPHARMA - IN TALKS FOR OPAGANIB CLINICAL ADVANCEMENT INCLUDING WHO SOLIDARITY CORE PLATFORM
REDHILL BIOPHARMA - OPAGANIB DEMONSTRATES SAFETY AND TOLERABILITY IN 470 CLINICAL TRIAL PARTICIPANTS
REDHILL BIOPHARMA - PHASE 3 DATA SHOW 70.2% MORTALITY REDUCTION WITH OPAGANIB AS ADD-ON TO STANDARD CARE
Source text: ID:nPre71l8Da
Further company coverage: [2RHy.F]